Freedom Broker initiated coverage of AngioDynamics (ANGO) with a Buy rating and $16 price target The firm sees an improved growth profile for the company due to its pivot to “higher-growth” medical technology platforms.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics: Improving Fundamentals and Strategic Transition Support Buy Rating and Higher Price Target
- AngioDynamics price target lowered to $16 from $18 at Canaccord
- AngioDynamics Earnings Call Highlights Med Tech Momentum
- Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
- AngioDynamics Posts Strong Q3 Results, Raises 2026 Guidance